CPRX: Catalyst Pharmaceuticals Inc Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 706.10
Enterprise Value ($M) 527.73
Book Value ($M) 220.22
Book Value / Share 2.14
Price / Book 3.21
NCAV ($M) 194.44
NCAV / Share 1.89
Price / NCAV 3.63

Profitability (mra)
Return on Invested Capital (ROIC) 0.20
Return on Assets (ROA) 0.23
Return on Equity (ROE) 0.25

Liquidity (mrq)
Quick Ratio 9.30
Current Ratio 9.64

Balance Sheet (mrq) ($M)
Current Assets 221.19
Assets 246.97
Liabilities 26.75
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 140.83
Operating Income 52.38
Net Income 39.48
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 60.37
Cash from Investing -11.02
Cash from Financing -8.14

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-15 13G/A Armistice Capital, Llc 9.30 -4.28
02-09 13G/A State Street Corp 4.90 -17.39
02-09 13G/A Vanguard Group Inc 4.69 -16.20
02-03 13G/A BlackRock Inc. 7.50 -0.77

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2022-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPOR
2022-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ☐ TRANSITION REPORT P
2022-03-16 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ☐ TRANSITION REPORT PUR
2021-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION R
2021-08-09 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2022-05-25 90,607 840,375 10.78
2022-05-24 76,720 689,791 11.12
2022-05-23 198,506 926,870 21.42
2022-05-20 148,739 896,102 16.60

(click for more detail)

Similar Companies
COLL – Collegium Pharmaceutical Inc CORT – Corcept Therapeutics Incorporated
CPIX – Cumberland Pharmaceuticals, Inc. CRBP – Corbus Pharmaceuticals Holdings Inc
CRBU – Caribou Biosciences, Inc.


Financial data and stock pages provided by
Fintel.io


Finpedia: Catalyst Pharmaceuticals